Letters
Stopping of Viagra trial
Viagra for fetal growth restriction: STRIDER Consortium replies to letter by Symonds and Budge
BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4872 (Published 22 November 2018) Cite this as: BMJ 2018;363:k4872
- Louise C Kenny, executive pro-vice chancellor1,
- Zarko Alfirevic, professor of fetal and maternal medicine1,
- Philip N Baker, pro-vice chancellor2,
- Wessel Ganzevoort, gynaecologist-perinatologist3,
- Christian Gluud, head of department4,
- Katie M Groom, associate professor5,
- Janus C Jakobsen, chief physician4,
- K Lim, head6,
- Laura A Magee, professor of women’s health7,
- Aris T Papageorghiou, professor of fetal medicine and obstetrics8,
- Peter von Dadelszen, professor of global women’s health7
- 1University of Liverpool, Liverpool, UK
- 2University of Leicester, Leicester, UK
- 3University of Amsterdam, Amsterdam, The Netherlands
- 4Copenhagen Trial Unit, Copenhagen, Denmark
- 5University of Auckland, Auckland, New Zealand
- 6Division of Maternal-Fetal Medicine, University of British Columbia, Vancouver, Canada
- 7King’s College London, London, UK
- 8St George’s, University of London, London, UK
- louise.kenny{at}liverpool.ac.uk
Symonds and Budge’s comments on a news article in The BMJ about the Dutch STRIDER trial are erroneous.12 They state that the “intervention resulted in 11 infant deaths due to lung related problems.” In fact, the study was stopped after an interim analysis that showed possible (but unproven) harm and to allow detailed review of the findings—specifically, an increased incidence …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.